Abametapir
Xeglyze (abametapir) is a small molecule pharmaceutical. Abametapir was first approved as Xeglyze on 2020-07-24. It is used to treat pediculus in the USA. Xeglyze's patents are valid until 2034-12-17 (FDA).
| Trade Name | Xeglyze |
|---|---|
| Common Name | Abametapir |
| Indication | pediculus |
| Drug Class | Pediculicide, metalloproteinase inhibitor |
